TRANSVAC is a pan-European Research Infrastructure project dedicated to accelerate vaccine development. It brings together leading European groups with longstanding experience in the field of vaccines.

Vaccine development is our best bet to tackle epidemic outbreaks and pandemics, but it’s time consuming and complex. Despite recent mobilization, researchers still have limited access to capabilities to transfer their discovery into clinical development and commercialization.

TRANSVAC is uniquely positioned to set up a Bio-Holding to transform European vaccine space

-70 Technical services across the R&D pipeline

>60 Vaccine development projects

Operates in ~10 European countries

TRANSVAC is a pan-European Research Infrastructure project dedicated to accelerate vaccine development. It brings together leading European groups with longstanding experience in the field of vaccines.

How to get involved?

TODAY: EXPANSION 2017-2021

Expanded infrastructure to 25+ partners and broadened services and support to veterinary and human vaccines (prophylactic and therapeutic)

PAST: BUILDING THE CORE 2009-2017

Core infrastructure with a limited number of partners and services for human prophylactic vaccines

FUTURE: HYBRID BIO-HOLDING 2021+

Create a Bio-Holding dedicated to business building to solidify impact at scale
TRANSVAC will establish a diverse portfolio of vaccine projects where one can invest.

TRANSVAC is well equipped to support the acceleration of successful vaccine businesses

- **Assays & Models**
- **Technology**
- **Adjuvants**
- **Regulatory and Clinical expertise**
- **Training**
- **Network**

*TRANSVAC & TRANSVAC2 EU-funded projects

TRANSVAC’S PATH FORWARD IS TO FOCUS ON BUSINESS BUILDING

- Active investor scouting and outreach support
- Evaluating commercial viability
- Portfolio Management
- Funding
- Business Building and Coaching

TRANSVAC will deliver commercial impact at scale as a vaccine business building entity

WHAT WOULD IT TAKE US TO GET THERE?

- **YEAR 1**
  - Briefing pack for the first candidates
  - Receive investments
  - Activate management team with strategic & commercial expertise

- **YEAR 2**
  - Expand service offer
  - Onboard & start securing deals for additional vaccine candidates
  - Continue building out portfolio of vaccines candidates
  - 1st performance evaluation milestone
  - First subsidiaries confirmed

CONTACT US

European Vaccine Initiative (EVI)

- Email: transvacinfo@euvaccine.eu
- Phone: 0049 17660863372

CONNECT

www.transvac.org/transvac-ds

- European Vaccine Initiative
- @EuropeVaccine

NETWORK
25 PARTNERS

FUNDER
EUROPEAN UNION

TIMELINE
1 JUNE 2020 - 31 MAY 2022

COORDINATOR
EUROPEAN VACCINE INITIATIVE

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 951668.